Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites
- 7 September 1995
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 50 (6) , 833-837
- https://doi.org/10.1016/0006-2952(95)00207-g
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Metabolic polymorphismsPharmacology & Therapeutics, 1993
- Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeastBiochemical Pharmacology, 1992
- Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteersChirality, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiaeBiochemistry, 1990
- Expression of human liver cytochrome P450 IIIA4 in yeastEuropean Journal of Biochemistry, 1990
- Synthesis of 10, 11-Dihydroxydihydroquinidine N-oxide, a New Metabolite of Quinidine. Preparation and 1H-nmr Spectroscopy of the Metabolites of Quinine and Quinidine and Conformational Analysis via 2D COSY NMR SpectroscopyJournal of Natural Products, 1990
- Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointesClinical Pharmacology & Therapeutics, 1988
- Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.British Journal of Clinical Pharmacology, 1986
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984